Agile Therapeutics, Inc. (AGRX)
Stock Price:
$2.63 USD
-0.08 (-2.78%)
Updated Aug 5, 2020 10:00 AM EDT - Market open
Key Info
| Market Cap |
228.93M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-21.82M |
| Shares Out |
87.21M |
| EPS (ttm) |
-0.37 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 5, 2020 |
| Last Price |
$2.63 |
| Previous Close |
$2.70 |
| Change ($) |
-0.08 |
| Change (%) |
-2.78% |
| Day's Open |
2.70 |
| Day's Range |
2.60 - 2.70 |
| Day's Volume |
276,139 |
| 52-Week Range |
0.35 - 4.77 |
More Stats
| Market Cap |
228.93M |
| Enterprise Value |
150.48M |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
87.21M |
| Float |
65.50M |
| EPS (basic) |
-0.36 |
| EPS (diluted) |
-0.37 |
| FCF / Share |
-0.25 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.69M |
| Short Ratio |
2.14 |
| Short % of Float |
6.38% |
| Beta |
1.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.41 |
| Revenue |
n/a |
| Operating Income |
-21.77M |
| Net Income |
-21.82M |
| Free Cash Flow |
-18.87M |
| Net Cash |
78.45M |
| Net Cash / Share |
0.90 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-20.15% |
| ROE |
-37.86% |
| ROIC |
-131.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.20*
(174.29% upside)
Low
6.00
Current: $2.63
High
8.00
Target: 7.20
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - | - |
| Operating Income | -18.86 | -19.54 | -26.81 | -29.72 | -33.09 | -18.52 | -12.73 | -23.32 |
| Net Income | -18.61 | -19.78 | -28.30 | -28.74 | -30.34 | -16.08 | -14.32 | -23.26 |
| Shares Outstanding | 49.43 | 34.32 | 30.94 | 28.27 | 22.02 | 11.39 | 0.05 | 0.04 |
| Earnings Per Share | -0.38 | -0.58 | -0.91 | -1.02 | -1.38 | -1.41 | -289.39 | -603.78 |
| Operating Cash Flow | -15.69 | -16.90 | -24.56 | -23.30 | -25.48 | -14.50 | -13.02 | -22.97 |
| Capital Expenditures | -0.10 | -0.32 | -1.31 | -0.03 | -0.29 | -0.10 | -4.95 | -6.69 |
| Free Cash Flow | -15.79 | -17.21 | -25.87 | -23.33 | -25.77 | -14.60 | -17.96 | -29.66 |
| Cash & Equivalents | 34.48 | 7.85 | 35.95 | 48.75 | 34.40 | 40.18 | 2.12 | 0.00 |
| Total Debt | - | - | 10.61 | 15.71 | 15.23 | 14.83 | 14.87 | - |
| Net Cash / Debt | 34.48 | 7.85 | 25.35 | 33.04 | 19.16 | 25.35 | -12.76 | 0.00 |
| Assets | 49.54 | 22.39 | 50.60 | 63.87 | 50.42 | 54.83 | 14.41 | - |
| Liabilities | 3.80 | 2.22 | 14.27 | 21.58 | 20.68 | 18.82 | 85.85 | - |
| Book Value | 45.75 | 20.17 | 36.32 | 42.29 | 29.74 | 36.01 | -71.44 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Agile Therapeutics, Inc. |
| Country |
United States |
| Employees |
15 |
| CEO |
Alfred F. Altomari |
Stock Information
| Ticker Symbol |
AGRX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: AGRX |
| IPO Date |
May 23, 2014 |
Description
Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.